Chile Radiotherapy Market Estimated At USD 36.0 Million By 2028


 San Francisco, 20 Sep 2021: The Report Chile Radiotherapy Market Size, Share & Trends Analysis Report By Type (External Beam, Internal Beam, Systemic Radiotherapy), By Application (Breast, Prostate, Lung, Colorectal, Head & Neck Cancer), And Segment Forecasts, 2021 - 2028

The Chile radiotherapy market size is expected to reach USD 36.0 million by 2028, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028. The increasing prevalence of cancer and rising healthcare expenditure are factors expected to propel the growth over the forecast period.

There is a significant gap between the required and installed radiotherapy capacity in Chile. As per a recently published report in the International Journal of Radiation Oncology, Chile had around 41 operative LINACs, which is less than the number required to meet the demand. This provides significant opportunities for growth for the market.

According to the International Agency of Research on Cancer (IARC), the estimated number of new lung cancer cases in Chile was around 4,000 in 2020. The number is expected to reach around 5,500 by 2030. The rising incidence of lung cancer can be attributed to increasing smoking. As per the national health survey, currently, 32.5% of the people in Chile are active smokers. The rising incidence of cancer is expected to drive market growth.

Moreover, companies are adopting strategies that allow them to use their resources to aid in the development of new products and enhance their supply chain. For instance, in August 2020, Siemens Healthcare GmbH announced the acquisition of Varian Medical Systems, Inc. in an all-cash transaction that accounted for USD 16.4 billion. This acquisition may enable the company to offer end-to-end oncology products to address the unmet medical needs of cancer treatment on a global scale.

Chronic adverse effects of radiotherapy occur after months or years of treatment. These effects depend on the total dose of radiotherapy received and the area of treatment. In some regions of the body, radiation treatment can lead to a buildup of body fluids and can cause lymphedema. Radiation exposure to healthy cells in the body can lead to apoptosis, senescence, necrosis, and terminal differentiation of healthy cells, which can lead to death. Radiotherapy weakens the body and can attenuate a body's receptiveness to radiation therapy or surgery. The adverse effects of radiation therapy may restrain market growth.

Access Research Report of Chile Radiotherapy Market https://www.grandviewresearch.com/industry-analysis/chile-radiotherapy-market-report

Chile Radiotherapy Market Report Highlights

  • In 2020, External Beam Radiation Therapy (EBRT) dominated the market and accounted for the largest revenue share of 86.5%. The high price and high installation base of EBRT equipment is one of the factors for the growth of the segment
  • The internal beam radiation therapy segment is expected to witness a lucrative CAGR of 6.9% during the forecast period. The ability to deliver the precise dose, increased patient preference, and cost-effectiveness are some factors driving the segment
  • The prostate cancer segment dominated the market and accounted for a share of 24.9% in the market in 2020 and is expected to continue its dominance throughout the forecast period. The high incidence and treatment rate of prostate cancer in Chile are some of the factors contributing to its dominance

List of Key Players of Chile Radiotherapy Market

  • Varian Medical Systems, Inc.
  • Elekta AB
  • Accuray Incorporated
  • Becton, Dickinson and Company
  • Isoray Medical
  • NTP Radioisotopes SOC Ltd.

Access Press Release of Chile Radiotherapy Market @ https://www.grandviewresearch.com/press-release/chile-radiotherapy-market-analysis

 

Comments

Popular posts from this blog

U.K. Point Of Sale Software Market To Expand Industry Growth At USD 1.05 Billion By 2028

Gas Detection Equipment Market Anticipated To Expand At A CAGR 9.7% From 2021 To 2028